If you missed it, check out this insightful article featuring our CTO, Phil Paik, on the future of DNA synthesis and its transformative potential in biotech. Discover how our cutting-edge enzymatic DNA synthesis technology is revolutionizing research and opening new frontiers in genetic science.
In another Q1 installment of the Pharma's Almanac roundtable, we asked biopharma SMEs about the strategies they were using to accelerate product development and to reach commercialization without compromising on quality. See the roundtable here: https://lnkd.in/d-_S-6Qs Our panel includes experts from Alconox Inc., AVANT BIO, Evonik, GBI Bio, Hamilton Company, Lonza, Mikart, LLC, Olon, Oxford Biomedica, PPD, Samsung Biologics, Serán BioScience, TriRx Pharmaceutical Services, LLC, Waters Corporation, Wheeler Bio, Inc., 908 Devices,3PBIOVIAN, AbCellera, Agilent Technologies, Astrea Bioseparations, BASF, BioCina, BioIVT, Bioluminescence Ventures, BIOSENIC S.A., C2 PHARMA, Catalent Pharma Solutions, Cellares, CellProthera SAS, Charles River Laboratories, Core Biogenesis, Cytiva, Donaldson, eClinical Solutions, Elixirgen Therapeutics, Inc., Empress Therapeutics, Enthought, Epocrates (use this one)... (cont.)
